Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models

Circulation

Volumn 99, Issue 1, 1999, Pages 105-110

  Benoit, Patrick ^a   Emmanuel, Florence ^a   Caillaud, Jean Michel ^a   Bassinet, Laurent ^a   Castro, Graciela ^b   Gallix, Pierre ^a   Fruchart, Jean Charles ^b   Branellec, Didier ^a   Denèfle, Patrice ^a   Duverger, Nicolas ^a  

^a SANOFI   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Apolipoproteins; Atherosclerosis; Genes

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; GENE TRANSFER; GENETIC ENGINEERING; IMMUNE RESPONSE; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; VIRUS EXPRESSION;

EID: 0033547789     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.1.105     Document Type: Article

References (40)

1. Genest JJ, Martin-Munley S, McNamara J, Ordovas J, Jenner J, Myers R, Silberman S, Wilson P, Salem D, Schaefer E. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025-2033.
2. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1:16-19.
3. Gordon D, Rifkind B. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
4. Higuchi K, Law S, Hoeg J, Schumacher U, Meglin N, Brewer HJ. Tissue-specific expression of apolipoprotein A-I (apoA-I) is regulated by the 5′-flanking region of the human apoA-I gene. J Biol Chem. 1988; 263:18530-18536.
5. Duverger N, Rader D, Duchateau P, Fruchart J, Castro G, Brewer HJ. Biochemical characterization of the three major subclasses of lipoprotein A-I preparatively isolated from human plasma. Biochemistry. 1993;32:12372-12379.
6. Badimon J, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234-1241.
7. Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, Sakai M, Hakamata H, Sakamoto Y, Natio M, Ruan Y, Takahashi K, Ohta T, Horiuchi S. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 1995;15:1882-1888.
8. Rubin E, Krauss R, Spangler E, Verstuyft J, Clift S. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267.
9. Duverger N, Kruth H, Emmanuel F, Caillaud J, Viglietta C, Castro G, Tailleux A, Fievet C, Fruchart J, Houdebine L, Denefle P. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation. 1996;94:713-717.
10. Paszty C, Maeda N, Verstuyft J, Rubin E. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94:899-903.
11. Plump A, Scott C, Breslow J. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994;91: 9607-9611.
12. Liu A, Lawn R, Verstuyft J, Rubin E. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. J Lipid Res. 1994;35:2263-2267.
13. Stein O, Dabach Y, Hollander G, BenNaim M, Halperin G, Breslow JL, Stein Y. Delayed loss of cholesterol from a localized lipoprotein depot in apolipoprotein A-I-deficient mice. Proc Natl Acad Sci U S A. 1997;94: 9820-9824.
14. Fielding C, Fielding P. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
15. Mackness M, Abbott C, Arrol S, Durrington P. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 1993;294(pt 3):829-834.
16. Mackness M, Arrol S, Abbott C, Durrington P. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
17. Suc I, Escargueil-Blanc I, Troly M, Salvayre R, Negre-Salvayre A. HDL and apoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol. 1997;17:2158-2166.
18. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987-1994.
19. Kopfler W, Willard M, Betz T, Willard J, Gerard R, Meidell R. Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol. Circulation. 1994;90:1319-1327.
20. DeGeest B, Zhao Z, Collen D, Holvoet P. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation. 1997;96:4349-4356.
21. Armentano D, Zabner J, Sacks C, Sookdeo CC, Smith MP, St George JA, Wadsworth SC, Smith AE, Gregory RJ. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol. 1997;71:2408-2416.
22. Guo Z, Wang L, Eisensmith R, Woo S. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther. 1996;3:802-810.
23. Tripathy S, Black H, Goldwasser E, Leiden J. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med. 1996;2: 545-550.
24. Stratford-Perricaudet L, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest. 1992;90:626-630.
25. Law S, Gray G, Brewer HJ. cDNA cloning of human apoA-I: amino acid sequence of preproapoA-I. Biochem Biophys Res Commun. 1983;112: 257-264.
26. Crouzet J, Naudin L, Orsini C, Vigne E, Ferrero L, Le RA, Benoit P, Latta M, Torrent C, Branellec D, Denefle P, Mayaux J, Perricaudet M, Yeh P. Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc Natl Acad Sci U S A. 1997;94:1414-1419.
27. Rubin E, Ishida B, Clift S, Krauss R. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci U S A. 1991;88:434-438.
28. Nichols AV, Krauss RM, Musliner TA. Nondenaturing polyacrylamide gradient gel electrophoresis. In: Segrest JP, Albers JJ, eds. Methods in Enzymology. New York, NY: Academic Press; 1986:417-431.
29. Betard C, Vudac N, Mezdour H, Nestruck AC, Leroy A, Fruchart JC. Standardization of an enzymatic assay for apolipoprotein A-I by using mixtures of monoclonal antibodies. J Clin Chem Clin Biochem. 1987;25: 893-899.
30. de la Llera Moya M, Alger V, Paul J, Fournier N, Moatti N, Giral P, Friday K, Rothblat G. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux: relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb. 1994;14:1056-1065.
31. Paigen B, Morrow A, Holmes P, Mitchell D, Williams R. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68: 231-240.
32. Castro G, Nihoul LP, Dengremont C, deGeitere C, Delfly B, Tailleux A, Fievet C, Duverger N, Denefle P, Fruchart JC, Rubin EM. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Biochemistry. 1997;36: 2243-2249.
33. Schultz J, Verstuyft J, Gong E, Nichols A, Rubin E. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 1993;365:762-764.
34. Yang Y, Nunes F, Berencsi K, Furth E, Gonczol E, Wilson J. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994;91:4407-4411.
35. Plump A, Smith J, Hayek T, Aalto-Setala K, Walsh A, Verstuyft J, Rubin E, Breslow J. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
36. Zhang S, Reddick R, Burkey B, Maeda N. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest. 1994;94:937-945.
37. Leiden J. Adenovirus-mediated gene transfer as an in vivo probe of lipoprotein metabolism. Circulation. 1996;94:2046-2051.
38. Wilson P. High-density lipoprotein, low-density lipoprotein and coronary artery disease. Am J Cardiol. 1990;66:7A-10A.
39. Rader D. Schaefer J, Lohse P, Ikewaki K, Thomas F, Harris W, Zech L, Dujovne C, Brewer HJ. Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism. 1993;42:1429-1434.
40. Seguret-Mace S, Latta-Mahieu M, Castro G, Luc G, Fruchart J, Rubin E, Denefle P, Duverger N. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation. 1996;94:2177-2184.